Alaunos Therapeutics
Yahoo Finance • last year
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and cl... Full story
Yahoo Finance • last year
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase... Full story
Yahoo Finance • last year
Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors,... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics Reports First Quarter 2023 Financial Results
Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023 Fully prepaid loan with Silicon Valley Bank; now a debt-free company Amended... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors,... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors
HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Generated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvironment; provides support for next generation TCR-T efforts Advancing TCR-T Library Program towards... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the four... Full story
Yahoo Finance • 2 years ago
12 Hot Penny Stocks On the Rise
In this article, we discuss 12 hot penny stocks on the rise. If you want to see more stocks in this selection, check out 5 Hot Penny Stocks On the Rise. Penny stocks usually trade under $5 and are favored by new investors or market partic... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock
HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the pricing of its underwritten public offering of... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics Announces Proposed Public Offering of Common Stock
HOUSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has commenced an underwritten public offer... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics Reports Third Quarter 2022 Financial Results
Presented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) Actively enr... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 1... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting
Data supports high-throughput screening process to identify neoantigen-reactive TCRsExclusive ownership of discovered KRAS mutation-reactive TCRshunTR enables expansion of the Company’s hotspot mutation targeted TCR library HOUSTON, Nov.... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September
HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced Kevin S. Boyle Sr., Chief Executive Officer and D... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy
First patient dosed achieved a confirmed objective partial response Second patient dosed at second dose level; cleared 28-day safety windowData to be presented on Friday, September 30 at 8:30am ET in a proffered presentation at the CRI-EN... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
HOUSTON, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has been accepted to present a proffered t... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics Reports Second Quarter 2022 Financial Results
Advancing TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; plan to present early data in 3Q 2022 at a scientific conference; moving ahead with second dose level Extended Cooperative... Full story
Yahoo Finance • 2 years ago
Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022
HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the second quarter ended June 30, 2022 on Monday, August 15, 202... Full story
